Shots:

• Wave to receive $22.5M for research & preclinical expenses and is eligible to receive opt-in payment- development & commercial milestone & will lead the manufacturing & joint clinical co-development activities. Both companies will share global costs & 50:50 profits
• Takeda’s gets an option to co-develop & co-commercialize CNS therapies for 3 targets- C9orf72- HTT & ATXN3- including WVE-004/003 & will lead the joint co-commercial activities in the US & all commercial activities outside of the US
• Takeda discontinues its discovery research with Wave for CNS programs & Takeda gets the right to license multiple preclinical programs for CNS indications over 4 yrs. research term

  Ref: Globe Newswire | Image:Takeda